---
layout: default
title: Alpha-Tocopherol Acetate
parent: 僅模型預測 (L5)
nav_order: 69
evidence_level: L5
indication_count: 10
---

# Alpha-Tocopherol Acetate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alpha-Tocopherol Acetate: From Antioxidant Supplement to Drug-Induced Osteoporosis

## One-Sentence Summary

Alpha-tocopherol acetate is the acetate ester form of Vitamin E (alpha-tocopherol), a fat-soluble antioxidant with no formally registered indications in Singapore.
The TxGNN model ranks **Drug-Induced Osteoporosis** as its highest-scoring predicted new indication,
with **0 clinical trials** and **0 publications** currently supporting this specific direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No approved indications on record in Singapore |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank for this submission. Based on well-established pharmacological knowledge, alpha-tocopherol acetate is the stable acetate ester form of Vitamin E. It is hydrolysed in the gut to release free alpha-tocopherol, the body's primary lipid-soluble chain-breaking antioxidant. Alpha-tocopherol terminates lipid peroxidation cascades in biological membranes by donating hydrogen atoms to peroxyl radicals, and it also modulates cell signalling through protein kinase C (PKC) inhibition.

Drug-induced osteoporosis — most commonly glucocorticoid-induced — operates primarily through suppression of osteoblast differentiation and proliferation, accelerated osteoclast-mediated bone resorption, and impaired calcium absorption. There is a plausible but indirect mechanistic link: oxidative stress is a recognised contributor to glucocorticoid-induced bone loss, and alpha-tocopherol's antioxidant properties could theoretically protect osteoblasts from reactive oxygen species (ROS)-mediated apoptosis. Animal studies have suggested Vitamin E may modestly improve bone turnover markers under oxidative stress conditions.

However, this connection is speculative. The TxGNN model's highest-scored prediction for this drug carries zero clinical or published literature support. The score is likely driven by knowledge graph node proximity between "Vitamin E / antioxidant" and the broad "osteoporosis" disease cluster, and may represent a model generalisation artefact. Notably, three other TxGNN predictions — diabetic retinopathy (L2, rank 10), cortical cataract (L3, rank 9), and diabetic cataract (L4, rank 2) — carry substantially stronger biological rationale and real-world evidence, and may represent more actionable candidates.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for drug-induced osteoporosis.

---

## Literature Evidence

Currently no related literature available for drug-induced osteoporosis.

---

## Singapore Market Information

Alpha-tocopherol acetate (DrugBank ID: DB14003) currently has **no HSA product registrations** in Singapore and is not marketed as a standalone pharmaceutical product.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|---------------------|
| — | No registered products found | — | — |

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Package insert warnings, contraindications, and drug interaction data were not retrievable in this evidence pack (Data Gaps DG001 and DG002). These must be resolved before any safety assessment can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a near-perfect TxGNN prediction score (99.99%), the complete absence of clinical trials and published literature for drug-induced osteoporosis, combined with only an indirect mechanistic link, is inconsistent with advancing this candidate. The prediction is most likely a knowledge graph propagation artefact rather than a true biological signal.

**To proceed, the following is needed:**

- **Resolve DG001 (Blocking):** Retrieve Singapore HSA package insert to obtain warnings and contraindications — required before any S1 safety screen
- **Resolve DG002 (High):** Query DrugBank API for full MOA data to enable mechanistic linkage analysis
- **Targeted literature search:** Conduct a specific PubMed/Cochrane search for alpha-tocopherol AND corticosteroid-induced osteoporosis to confirm the evidence void
- **Consider reprioritisation:** The top-ranked TxGNN prediction (drug-induced osteoporosis, L5) is the weakest candidate in this evidence pack. The following indications carry meaningfully stronger evidence and may merit priority review:
  - **Diabetic Retinopathy** (rank 10): L2 evidence — 2 completed clinical trials (Phase 2 & Phase 3) + 20 publications, mechanistically well-supported (PKC-β inhibition, lipid peroxidation suppression); decision stage S2, **Proceed with Guardrails**
  - **Cortical Cataract** (rank 9): L3 evidence — 9 publications including 2 RCTs, strong mechanistic rationale (membrane lipid protection in lens cortex); decision stage S2, **Research Question**
  - **Diabetic Cataract** (rank 2): L4 evidence — 11 publications, mechanistically plausible via oxidative stress pathway; decision stage S1, **Research Question**

> ⚠️ **Disclaimer:** This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any clinical application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

